RSS

Novo Holdings

Polyphor — a clinical stage Swiss biopharmaceutical company — has raised CHF 6.8 million from the Novo REPAIR Impact Fund to accelerate the development of novel antibiotics against multi-drug resistant Gram-negative pathogens. more

News

Biopharmaceutical company, NBE Therapeutics, has closed an extension of its Series B financing round with CHF 20 million investment from Novo Holdings, making it a major shareholder. more

News